Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date | Reported DateTime | Company | Symbol | Insider Relationship | Shares Traded | Average Price | Total Amount | Shares Owned | Filing |
| 2023-05-22 Sale | 2023-05-24 4:38 pm | TCR2 THERAPEUTICS INC. | TCRR | GADICKE ANSBERT Director 10% Owner | 70,170 | $1.88 | $131,920 | 7,529,946 (Indirect) | View |
| 2022-01-04 Sale | 2022-01-06 4:12 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 245,469 | $42.58 | $10,452,334 | 4,484,728 (Indirect) | View |
| 2021-12-03 Sale | 2021-12-07 6:33 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 83,390 | $33.73 | $2,812,428 | 4,730,197 (Indirect) | View |
| 2021-11-30 Sale | 2021-12-02 6:53 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 139,773 | $34.47 | $4,817,417 | 4,813,587 (Indirect) | View |
| 2021-11-26 Sale | 2021-11-30 4:49 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 38,566 | $35.18 | $1,356,825 | 4,953,360 (Indirect) | View |
| 2021-11-22 Sale | 2021-11-24 6:38 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 129,617 | $36.61 | $4,744,666 | 5,007,597 (Indirect) | View |
| 2021-11-02 Purchase | 2021-11-04 5:37 pm | Entrada Therapeutics Inc. | TRDA | MPM BioVentures 2014 L.P. EVNIN LUKE GADICKE ANSBERT MPM BioVentures 2014 (B) L.P. MPM Asset Management Investors BV2014 LLC MPM BioVentures 2014 LLC MPM BioVentures 2014 GP LLC MPM BIOVENTURES 2018 (B) L.P. MPM ASSET MANAGEMENT INVESTORS BV2018 LLC 10% Owner | 100,000 | $20 | $2,000,000 | 4,425,784 (Indirect) | View |
| 2021-10-15 Sale | 2021-10-18 4:33 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 28,615 | $27.45 | $785,384 | 5,137,214 (Indirect) | View |
| 2021-10-12 Sale | 2021-10-14 5:26 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 95,002 | $27.21 | $2,584,606 | 5,165,829 (Indirect) | View |
| 2021-10-07 Sale | 2021-10-12 4:33 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 87,006 | $27.23 | $2,368,800 | 5,260,831 (Indirect) | View |
| 2021-10-01 Sale | 2021-10-05 4:31 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 46,130 | $27.05 | $1,247,590 | 5,347,837 (Indirect) | View |
| 2021-09-28 Sale | 2021-09-30 5:05 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 35,990 | $27 | $971,730 | 5,393,967 (Indirect) | View |
| 2021-09-23 Sale | 2021-09-27 5:51 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 89,476 | $27.76 | $2,484,094 | 5,429,957 (Indirect) | View |
| 2021-09-21 Sale | 2021-09-23 4:18 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 56,779 | $27.5 | $1,561,394 | 5,519,433 (Indirect) | View |
| 2021-09-16 Sale | 2021-09-20 6:30 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 152,711 | $28.38 | $4,334,452 | 5,576,212 (Indirect) | View |
| 2021-09-16 Sale | 2021-09-20 5:30 pm | Cullinan Oncology Inc. | CGEM | GADICKE ANSBERT Director 10% Owner | 3,556 | $29.06 | $103,337 | 7,892,819 (Indirect Direct) | View |
| 2021-09-14 Sale | 2021-09-16 4:46 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 76,417 | $27.7 | $2,116,733 | 5,728,923 (Indirect) | View |
| 2021-09-14 Sale | 2021-09-16 4:44 pm | Cullinan Oncology Inc. | CGEM | GADICKE ANSBERT Director 10% Owner | 15,401 | $29.17 | $449,174 | 7,896,375 (Indirect Direct) | View |
| 2021-09-09 Sale | 2021-09-13 7:02 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 96,456 | $28.32 | $2,731,460 | 5,805,340 (Indirect) | View |
| 2021-09-09 Sale | 2021-09-13 6:22 pm | Cullinan Oncology Inc. | CGEM | GADICKE ANSBERT Director 10% Owner | 26,468 | $29.23 | $773,720 | 7,911,776 (Indirect Direct) | View |
| 2021-09-07 Sale | 2021-09-08 7:19 pm | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 71,232 | $29.03 | $2,067,786 | 5,933,136 (Indirect) | View |
| 2021-09-03 Sale | 2021-09-08 6:17 pm | Cullinan Oncology Inc. | CGEM | GADICKE ANSBERT Director 10% Owner | 55,364 | $29.2 | $1,616,749 | 7,938,244 (Indirect Direct) | View |
| 2021-08-31 Sale | 2021-09-02 5:25 pm | Cullinan Oncology Inc. | CGEM | GADICKE ANSBERT Director 10% Owner | 27,669 | $29.5 | $816,352 | 7,993,608 (Indirect Direct) | View |
| 2021-08-27 Sale | 2021-08-31 4:48 pm | Cullinan Oncology Inc. | CGEM | GADICKE ANSBERT Director 10% Owner | 50,489 | $29.24 | $1,476,135 | 8,021,277 (Indirect Direct) | View |
| 2021-08-23 Sale | 2021-08-25 7:41 pm | Cullinan Oncology Inc. | CGEM | GADICKE ANSBERT Director 10% Owner | 120,592 | $29.29 | $3,531,820 | 8,071,766 (Indirect Direct) | View |
| 2021-08-11 Sale | 2021-08-12 4:54 pm | Cullinan Oncology Inc. | CGEM | GADICKE ANSBERT Director 10% Owner | 2,857 | $29.05 | $82,996 | 8,192,298 (Indirect Direct) | View |
| 2021-07-09 Sale | 2021-07-13 4:21 pm | Repare Therapeutics Inc. | RPTX | GADICKE ANSBERT 10% Owner | 62,079 | $33.55 | $2,082,868 | 3,882,485 (Indirect) | View |
| 2021-06-28 Sale | 2021-06-30 5:25 pm | Repare Therapeutics Inc. | RPTX | GADICKE ANSBERT 10% Owner | 19,200 | $34.06 | $653,925 | 3,944,564 (Indirect) | View |
| 2021-06-24 Sale | 2021-06-28 4:07 pm | Repare Therapeutics Inc. | RPTX | GADICKE ANSBERT 10% Owner | 28,688 | $33.51 | $961,457 | 3,963,764 (Indirect) | View |
| 2021-06-21 Sale | 2021-06-23 5:38 pm | Repare Therapeutics Inc. | RPTX | GADICKE ANSBERT 10% Owner | 42,798 | $34.36 | $1,470,441 | 3,992,452 (Indirect) | View |
| 2021-06-17 Sale | 2021-06-21 4:06 pm | Repare Therapeutics Inc. | RPTX | GADICKE ANSBERT 10% Owner | 41,518 | $33.77 | $1,402,002 | 4,035,250 (Indirect) | View |
| 2021-06-14 Sale | 2021-06-16 5:09 pm | Repare Therapeutics Inc. | RPTX | GADICKE ANSBERT 10% Owner | 6,227 | $33.25 | $207,066 | 4,076,768 (Indirect) | View |
| 2021-06-08 Sale | 2021-06-10 4:04 pm | Repare Therapeutics Inc. | RPTX | GADICKE ANSBERT 10% Owner | 61,430 | $34.05 | $2,091,457 | 4,082,995 (Indirect) | View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date | Reported DateTime | Exercisable Expiration | Company | Symnbol | Insider Relationship | Shares Traded | Conversion Price | Shares Owned | Filing |
| 2023-06-01 Other | 2023-06-05 4:35 pm | N/A N/A | TCR2 THERAPEUTICS INC. | TCRR | GADICKE ANSBERT Director 10% Owner | 7,529,946 | $0 | 7,529,946 (Indirect) | View |
| 2023-05-22 Exercise | 2023-05-24 4:38 pm | N/A N/A | TCR2 THERAPEUTICS INC. | TCRR | GADICKE ANSBERT Director 10% Owner | 178,269 | $0.74 | 7,529,946 (Indirect) | View |
| 2023-05-22 Exercise | 2023-05-24 4:38 pm | 2016-12-13 2026-12-12 | TCR2 THERAPEUTICS INC. | TCRR | GADICKE ANSBERT Director 10% Owner | 178,269 | $0 | 7,529,946 (Indirect) | View |
| 2021-12-21 Ownership | 2023-02-10 4:26 pm | N/A 2030-10-28 | Cullinan Oncology Inc. | CGEM | GADICKE ANSBERT Former Director Director 10% Owner | 350,938 | $0 | 8,243,757 (Direct) | View |
Ownership | 2023-02-10 4:26 pm | N/A N/A | Cullinan Oncology Inc. | CGEM | GADICKE ANSBERT Former Director Director 10% Owner | 0 | $0 | 8,243,757 (Indirect) | View |
| 2021-12-21 Ownership | 2023-02-10 4:26 pm | N/A N/A | Cullinan Oncology Inc. | CGEM | GADICKE ANSBERT Former Director Director 10% Owner | 350,938 | $4.3 | 8,243,757 (Direct) | View |
| 2022-07-28 Option Award | 2022-08-01 4:34 pm | N/A N/A | Allovir Inc. | ALVR | GADICKE ANSBERT Director 10% Owner | 3,253,796 | $4.61 | 16,704,963 (Indirect) | View |
| 2022-06-22 Option Award | 2022-06-23 6:22 pm | N/A 2032-06-21 | Cullinan Oncology Inc. | CGEM | GADICKE ANSBERT Director | 16,475 | $0 | 16,475 (Direct) | View |
| 2022-05-17 Option Award | 2022-05-19 4:27 pm | N/A 2032-05-16 | Allovir Inc. | ALVR | GADICKE ANSBERT Director 10% Owner | 27,500 | $0 | 27,500 (Direct) | View |
| 2021-09-16 Option Award | 2022-03-25 7:32 pm | N/A 2031-09-15 | Cullinan Oncology Inc. | CGEM | GADICKE ANSBERT Director 10% Owner | 7,800 | $0 | 7,800 (Direct) | View |
| 2021-11-17 Other | 2021-11-24 6:38 pm | N/A N/A | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 15,671 | $0 | 5,007,597 (Indirect) | View |
| 2021-11-02 Conversion | 2021-11-04 5:37 pm | N/A N/A | Entrada Therapeutics Inc. | TRDA | MPM BioVentures 2014 L.P. EVNIN LUKE GADICKE ANSBERT MPM BioVentures 2014 (B) L.P. MPM Asset Management Investors BV2014 LLC MPM BioVentures 2014 LLC MPM BioVentures 2014 GP LLC MPM BIOVENTURES 2018 (B) L.P. MPM ASSET MANAGEMENT INVESTORS BV2018 LLC 10% Owner | 35,626,700 | $0 | 4,425,784 (Indirect) | View |
Ownership | 2021-10-28 8:45 pm | N/A N/A | Entrada Therapeutics Inc. | TRDA | MPM BioVentures 2014 L.P. EVNIN LUKE GADICKE ANSBERT MPM BioVentures 2014 (B) L.P. MPM Asset Management Investors BV2014 LLC MPM BioVentures 2014 LLC MPM BioVentures 2014 GP LLC MPM BIOVENTURES 2018 (B) L.P. MPM ASSET MANAGEMENT INVESTORS BV2018 LLC 10% Owner | 0 | $0 | 4,325,784 (Indirect) | View |
| 2021-09-07 Other | 2021-09-08 7:19 pm | N/A N/A | iTeos Therapeutics Inc. | ITOS | GADICKE ANSBERT UBS Oncology Impact Fund L.P. BioImpact Capital LLC Oncology Impact Fund (Cayman) Management L.P. 10% Owner | 31,340 | $0 | 5,933,136 (Indirect) | View |